|Bid||27.45 x 1000|
|Ask||27.48 x 800|
|Day's Range||27.37 - 28.02|
|52 Week Range||16.56 - 29.44|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||78.32|
|Earnings Date||May 27, 2019 - May 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.38|
A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for Horizon’s investigational medicine teprotumumab to change the treatment paradigm. The Biologics License Application (BLA) for teprotumumab is currently being reviewed by the U.S. Food and Drug Administration (FDA) and if approved, teprotumumab could be the first FDA-approved medicine for active TED.
Horizon Therapeutics plc today announced that the company will participate in the following conference in September:
Horizon Therapeutics PLC (NASDAQ: HZNP ), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary ...
Horizon Therapeutics plc (HZNP) today announced the launch of RAREisCommunity.com, a go-to resource for the more than 350 million people around the world living with rare disease. This website is the latest expansion of Horizon’s #RAREis™ program, which aims to elevate the voices, faces and experiences of the rare disease community. “One common theme that has arisen from our conversations with families and advocates in the rare disease community is the need to bring together resources and advice to help those living with rare diseases and their caregivers navigate through the challenges of life’s transitions,” said Ann Marie Bingo, associate director, patient advocacy, Horizon.
Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients. The Canadian government announced final regulations meant to cut drug spending on Friday. The reforms expand the Patented Medicine Prices Review Board's (PMPRB) powers, and among other things give it the ability to consider the cost-effectiveness of medications.
EVP, Corporate Affairs, CCO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Geoffrey M. Continue reading...
Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million --
The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Therapeutics plc (HZNP) announced today that the company has won a Gold International CSR Excellence Award in the Large Business category for its partnership with Chicago-based school, Perspectives Math and Science Academy (MSA). A video highlighting the partnership can be found here. Since 2016, Horizon’s partnership with MSA has focused on three areas of giving: infrastructure, programming and employee engagement.
Investors are always looking for growth in small-cap stocks like Horizon Therapeutics Public Limited Company...
Horizon Therapeutics plc (HZNP) announced today that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets. If approved by the FDA, this new dosage form would provide another option for patients, in addition to the currently available PROCYSBI delayed-release capsules. The capsules are FDA-approved for children one year of age and older and adults living with nephropathic cystinosis.
Horizon Therapeutics plc (HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com.
Horizon Therapeutics plc (HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $65 million in cash on hand, to redeem or prepay $625 million of its outstanding debt, consisting of (i) the outstanding $225 million principal amount of its 6.625% senior notes due 2023, (ii) the outstanding $300 million principal amount of its 8.75% senior notes due 2024 and (iii) $100 million of the outstanding principal amount of senior secured term loans under Horizon’s credit agreement, as well as to pay the related premiums and fees and expenses, excluding accrued interest, associated with the redemption and prepayment.
Horizon Therapeutics plc (HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027. Horizon currently expects to use the net proceeds from the offering, together with approximately $64 million in cash on hand, to redeem $525 million of its outstanding debt, consisting of the outstanding (i) $225 million principal amount of its 6.625% senior notes due 2023 and (ii) $300 million principal amount of its 8.75% senior notes due 2024, as well as to pay the related premiums, and fees and expenses, excluding accrued interest, associated with the redemption. The proposed redemption of Horizon’s existing senior notes is being conducted to further Horizon’s deleveraging strategy, to reduce interest expense and to extend the maturity of its debt obligations to improve its capital structure.
Horizon Therapeutics plc announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational medicine teprotumumab for the treatment of active thyroid eye disease .
Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let's study the drivers and risks for both these rare disease players in greater detail.
Today marks the launch of a new patient empowerment and disease education initiative called Eyes on Graves’, created to bring attention, education and resources to people living with Graves’ disease and/or thyroid eye disease (TED). In time for Graves’ Disease Awareness Month in July, Eyes on Graves’ was created through a new collaboration called the Graves’ and TED Council – a group of people living with both diseases and their loved ones whose mission is to raise awareness and understanding of Graves’ disease and TED among physicians, patients and caregivers, leading to improved care and patient support. Eyes on Graves’ is supported by the Graves’ Disease and Thyroid Foundation (GDATF) and Horizon Therapeutics.